$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Detailed explanation of whether Asciminib/Asciminib has been included in medical insurance and reimbursement policy
2026-02-01 22:25:32
Check Details
Detailed explanation of the functions, efficacy and indications of ritexitinib (Lefenox)
2026-02-01 22:25:32
Check Details
Which company is Sparsentan developed by and what is the background of the drug?
2026-02-01 22:25:32
Check Details
Common side effects of ixazomib (Enleri) and patient medication safety guidance
2026-02-01 22:25:32
Check Details
Will rubitin/rubicatin (Zanbiga) withdraw from clinical trials for small cell lung cancer?
2026-02-01 22:25:32
Check Details
An introduction to the official launch time of Elacetrant in the country and related approval progress
2026-02-01 22:25:32
Check Details
What is F/TAF and a detailed introduction to its main clinical effects and indications
2026-02-01 22:25:32
Check Details
Detailed introduction to the common side effects of Febuxostat (Febuxostat) and how to deal with them when they occur
2026-02-01 22:25:32
Check Details
Which company produces furmonertinib and its corporate background?
2026-02-01 22:25:32
Check Details
How much does a box of ensifentrine-Ohtuvayre cost? Analysis of price fluctuations and purchasing channels
2026-02-01 22:25:32
Check Details
Roaccutane (isotretinoin) (Isotretinoin) soft capsule instructions content and detailed medication guidance analysis
2026-02-01 22:25:32
Check Details
Detailed analysis of the efficacy and common side effects of Doxorubicin and medication risk tips
2026-02-01 22:25:32
Check Details
1
2
...
2112
2113
2114
2115
2116
2117
2118
...
10213
10214
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
2
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
3
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
4
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition
5
Pretomanid for Drug-Resistant TB: Risks and Management of 3-Year Treatment
6
SKYSCRAPER-02C Study: New Hope for Extensive-Stage Small Cell Lung Cancer Treatment
7
LPCAT3: The Key Player in MASH Progression to Hepatocellular Carcinoma
8
Tucatinib (Tukysa): A Precision Medicine for HER2-Positive Breast & Colorectal Cancer
9
Venetoclax Therapy Guidelines: Balancing Precision Targeting with Risk Management
10
Global Breakthrough: Pralsetinib - Precision Medicine for RET Mutation-Driven Cancers
11
A Comprehensive Guide to Benralizumab Adverse Reactions: Prevention and Management
12
Lemborexant: A Dual Orexin Receptor Antagonist Revolutionizing Insomnia Treatment